Onco-hypertension is an emerging field investigating the relationship between hypertension and cancer. This paper details one part of this relationship—the effect of anti-cancer agents on blood pressure. We review the evidence linking targeted therapies, immunotherapy, traditional chemotherapies, and hormonal agents with hypertension. Proposed pathophysiological mechanisms vary by drug but include endothelial dysfunction, altered sodium homeostasis, and nephrotoxicity. Despite growing interest in the field, there is a paucity of data on the clinical significance of treatment related hypertension and the optimal management strategy. This should be a focus of future studies.
KidoguchiSSuganoNTokudomeG, et al. New concept of onco-hypertension and future perspectives. Hypertension2021; 77: 16–27.
2.
American Cancer Society. Cancer treatment & survivorship facts & figures 2019 – 2021. Atlanta: American Cancer Society, 2019.
3.
StrongmanHGaddSMatthewsA, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet2019; 394: 1041–1054.
4.
WheltonPKCareyRMAronowWS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension2018; 71: 1269–1324.
5.
National Cancer Institute DCTD Division of Cancer Treatment & Diagnosis. Common terminology criteria for adverse events (CTCAE). 2017.
6.
WheltonPKCareyRMAronowWS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension2018; 71: e13–e115.
7.
WilliamsBManciaGSpieringW, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens2018; 36: 1953–2041.
8.
Abdel-QadirHEthierJLLeeDS, et al. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev2017; 53: 120–127.
9.
AnMMZouZShenH, et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol2010; 66: 813–821.
10.
ChenJLuYZhengY.Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials. Drug Des Devel Ther2015; 9: 4751–4760.
11.
HurwitzHIDouglasPSMiddletonJP, et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist2013; 18: 273–280.
12.
LiuBDingFLiuY, et al. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget2016; 7: 67661–67673.
13.
WuSChenJJKudelkaA, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol2008; 9: 117–123.
14.
TotzeckMMincuRIMrotzekS, et al. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol2018; 25: 482–494.
15.
ZhuXStergiopoulosKWuS.Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol2009; 48: 9–17.
16.
HamnvikOPChoueiriTKTurchinA, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer2015; 121: 311–319.
17.
RobinsonESMatulonisUAIvyP, et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol2010; 5: 477–483.
18.
MaitlandMLKaszaKEKarrisonT, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res2009; 15: 6250–6257.
19.
RiniBIMelicharBUedaT, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol2013; 14: 1233–1242.
20.
LankhorstSSalehLDanserAJ, et al. Etiology of angiogenesis inhibition-related hypertension. Curr Opin Pharmacol2015; 21: 7–13.
21.
KimJJVaziriSARiniBI, et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer2012; 118: 1946–1954.
22.
SchneiderBPLiLShenF, et al. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer2014; 111: 1241–1248.
23.
MirORopertSAlexandreJ, et al. Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol2009; 20: 967–970.
24.
ScartozziMGaliziaEChiorriniS, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol2009; 20: 227–230.
25.
WickASchaferNDornerN, et al. Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome. J Neurooncol2010; 97: 157–158.
26.
CaiJMaHHuangF, et al. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World J Surg Oncol2013; 11: 306.
27.
CalettiSPainiACoschignanoMA, et al. Management of VEGF-Targeted Therapy-Induced Hypertension. Curr Hypertens Rep2018; 20: 68.
28.
LankhorstSKappersMHvan EschJH, et al. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J Hypertens2013; 31: 444–454; discussion 454.
29.
PandeyAKSinghiEKArroyoJP, et al. Mechanisms of VEGF (Vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension2018; 71: e1–e8.
30.
RobinsonESKhankinEVKarumanchiSA, et al. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol2010; 30: 591–601.
31.
TouyzRMLangNNHerrmannJ, et al. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension2017; 70: 220–226.
KappersMHde BeerVJZhouZ, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension2012; 59: 151–157.
34.
MouradJJdes GuetzGDebbabiH, et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol2008; 19: 927–934.
35.
VeroneseMLMosenkisAFlahertyKT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol2006; 24: 1363–1369.
36.
JamesPAOparilSCarterBL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA2014; 311: 507–520.
37.
AziziMChedidAOudardS.Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med2008; 358: 95–97.
38.
PlummerCMichaelAShaikhG, et al. Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. Br J Cancer2019; 121: 109–116.
39.
CaroJMoralesEGutierrezE, et al. Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors. J Clin Hypertens (Greenwich)2013; 15: 215–216.
40.
TlemsaniCMirOBoudou-RouquetteP, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol2011; 6: 253–258.
41.
DobbinSJHCameronACPetrieMC, et al. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart2018; 104: 1995–2002.
42.
MaitlandMLBakrisGLBlackHR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst2010; 102: 596–604.
43.
BairSMChoueiriTKMoslehiJ.Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med2013; 23: 104–113.
44.
NazerBHumphreysBDMoslehiJ.Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation2011; 124: 1687–1691.
45.
VersmissenJMirabito ColafellaKMKoolenSLW, et al. Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension. Cardiovasc Res2019; 115: 904–914.
46.
WalianySSainaniKLParkLS, et al. Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor. JACC CardioOncol2019; 1: 24–36.
PatelSDushenkovAJungsuwadeeP, et al. Team-based approach to management of hypertension associated with angiogenesis inhibitors. J Cardiovasc Transl Res2020; 13: 463–477.
49.
CopurMSObermillerA.An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer2011; 10: 151–156.
50.
LangenbergMHvan HerpenCMDe BonoJ, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. J Clin Oncol2009; 27: 6152–6159.
51.
BottinorWJShueyMMManouchehriA, et al. Renin-angiotensin-aldosterone system modulates blood pressure response during vascular endothelial growth factor receptor inhibition. JACC CardioOncol2019; 1: 14–23.
52.
MensahFABlaizeJPBryanLJ.Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. Onco Targets Ther2018; 11: 4817–4827.
53.
FrumanDAChiuHHopkinsBD, et al. The PI3K Pathway in Human Disease. Cell2017; 170: 605–635.
54.
DreylingMSantoroAMollicaL, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol2020; 95(4):362–371.
55.
PatnaikAApplemanLJTolcherAW, et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Ann Oncol2016; 27: 1928–1940.
56.
DreylingMMorschhauserFBouabdallahK, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol2017; 28: 2169–2178.
57.
PerrottaMLemboGCarnevaleD.The multifaceted roles of PI3Kgamma in hypertension, vascular biology, and inflammation. Int J Mol Sci2016; 17: 1858.
58.
EltantawyAVallejosXSebeaE, et al. Copanlisib: an intravenous phosphatidylinositol 3-kinase (PI3K) inhibitor for the treatment of relapsed follicular lymphoma. Ann Pharmacother2019; 53: 954–958.
59.
MorschhauserFMachielsJPSallesG, et al. On-target pharmacodynamic activity of the PI3K inhibitor copanlisib in paired biopsies from patients with malignant lymphoma and Advanced solid tumors. Mol Cancer Ther2020; 19: 468–478.
60.
SerontERotteySFilleulB, et al. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma. BJU Int2016; 118: 408–415.
61.
Aliqopa (package insert).Whippany, NJ: Bayer Health Pharmaceuticals, Inc., 2017.
62.
ChesonBDO’BrienSEwerMS, et al. Optimal management of adverse events from copanlisib in the treatment of patients with non-hodgkin lymphomas. Clin Lymphoma Myeloma Leuk2019; 19: 135–141.
63.
HideshimaTRichardsonPGAndersonKC.Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther2011; 10: 2034–2042.
64.
BishnoiRXieZShahC, et al. Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis. Cancer Med2021; 10(1): 70–78.
65.
ColeDCFrishmanWH.Cardiovascular complications of proteasome inhibitors used in multiple myeloma. Cardiol Rev2018; 26: 122–129.
66.
FakhriBFialaMAShahN, et al. Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database. Cancer2020; 126: 808–813.
67.
DimopoulosMAGoldschmidtHNiesvizkyR, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol2017; 18: 1327–1337.
68.
PlummerCDriessenCSzaboZ, et al. Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J2019; 9: 26.
69.
WaxmanAJClasenSHwangWT, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol2018; 4: e174519.
AbbasAMirzaMMGantiAK, et al. Renal toxicities of targeted therapies. Target Oncol2015; 10: 487–499.
72.
BittingRLHealyPCreelPA, et al. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer2014; 12: 241–250.
73.
KaplanBQaziYWellenJR.Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando)2014; 28: 126–133.
74.
KatsiVMagkasNGeorgiopoulosG, et al. Arterial hypertension in patients under antineoplastic therapy: a systematic review. J Hypertens2019; 37: 884-901.
75.
BendtsenMAFGrimmDBauerJ, et al. Hypertension caused by lenvatinib and everolimus in the treatment of metastatic renal cell carcinoma. Int J Mol Sci2017; 18: 1736.
76.
U.S. Food & Drug Administration. Highlights of prescribing information. 2016.
77.
WenTWangJShiY, et al. Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances. Leukemia2021; 35: 312–332.
78.
CoutreSEByrdJCHillmenP, et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv2019; 3: 1799–1807.
79.
ByrdJCWierdaWGSchuhA, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood2020; 135: 1204–1213.
80.
DickersonTWiczerTWallerA, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood2019; 134: 1919–1928.
81.
HerrmannSMPerazellaMA.Immune checkpoint inhibitors and immune-related adverse renal events. Kidney Int Rep2020; 5: 1139–1148.
82.
JohnsonDBBalkoJMComptonML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med2016; 375: 1749-1755.
83.
KustersPJHLutgensESeijkensTTPExploring immune checkpoints as potential therapeutic targets in atherosclerosis. Cardiovasc Res2018; 114: 368–377.
84.
PerazellaMAShiraliAC.Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?Kidney Int2020; 97: 62–74.
85.
PatrinelyJRJr.YoungACQuachH, et al. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. Eur J Cancer2020; 135: 211–220.
86.
PuyoSMontaudonDPourquierP.From old alkylating agents to new minor groove binders. Crit Rev Oncol Hematol2014; 89: 43–61.
87.
EastmanA.Alkylating and platinum-based agents. Curr Opin Oncol1990; 2: 1109–1114.
88.
Abi AadSPierceMBarmaimonG, et al. Hypertension induced by chemotherapeutic and immunosuppresive agents: a new challenge. Crit Rev Oncol Hematol2015; 93: 28–35.
BerendesECullenPVan AkenH, et al. Endogenous glycosides in critically ill patients. Crit Care Med2003; 31: 1331–1337.
91.
GravesSWEderJPSchryberSM, et al. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clin Sci (Lond)1989; 77: 501–507.
92.
KnijnenburgSLJaspersMWvan der PalHJ, et al. Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors. Clin J Am Soc Nephrol2012; 7: 1416–1427.
93.
ColleoniMRoccaASandriMT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol2002; 13: 73–80.
94.
Al-HashmiSBoelsPJZadjaliF, et al. Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase. PLoS One2012; 7: e30897.
95.
HassenLJLenihanDJBaligaRR.Hypertension in the Cardio-Oncology Clinic. Heart Fail Clin2019; 15: 487–495.
96.
GeisbergCASawyerDB.Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep2010; 12: 404–410.
97.
DasariSTchounwouPB.Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol2014; 740: 364–378.
98.
HerradonEGonzalezCUrangaJA, et al. Characterization of cardiovascular alterations induced by different chronic cisplatin treatments. Front Pharmacol2017; 8: 196.
99.
NuverJSmitAJvan der MeerJ, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol2005; 23: 9130–9137.
100.
MeinardiMTGietemaJAvan der GraafWT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol2000; 18: 1725–1732.
101.
SagstuenHAassNFossaSD, et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol2005; 23: 4980–4990.
102.
StrumbergDBruggeSKornMW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol2002; 13: 229–236.
103.
LauritsenJHansenMKBandakM, et al. Cardiovascular risk factors and disease after Male germ cell cancer. J Clin Oncol2020; 38: 584–592.
104.
NuverJSmitAJWolffenbuttelBH, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol2005; 23: 3718–3725.
105.
SoultatiAMountziosGAvgerinouC, et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev2012; 38: 473–483.
106.
IzzedineHIsnard-BagnisCLaunay-VacherV, et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant2006; 21: 3038–3045.
107.
PhelanPJLiewAMageeC.A case of progressive hypertension preceding gemcitabine-associated thrombotic microangiopathy complicated by acute kidney injury and stroke. Ren Fail2009; 31: 743–744.
108.
MoudiMGoRYienCY, et al. Vinca alkaloids. Int J Prev Med2013; 4: 1231–1235.
109.
NoorBAkhavanSLeuchterM, et al. Quantitative assessment of cardiovascular autonomic impairment in cancer survivors: a single center case series. Cardiooncology2020; 6: 11.
110.
RocaEBrueraEPolitiPM, et al. Vinca alkaloid-induced cardiovascular autonomic neuropathy. Cancer Treat Rep1985; 69: 149–151.
111.
PufallMA.Glucocorticoids and Cancer. Adv Exp Med Biol2015; 872: 315–333.
BremAS.Insights Into Glucocorticoid-Associated Hypertension. Am J Kidney Dis2001; 37: 1–10.
114.
Bernal-MizrachiCWengSFengC, et al. Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice. Nat Med2003; 9: 1069–1075.
115.
SatoAFunderJWOkuboM, et al. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens1995; 8: 823–828.
116.
GrossmanAMesserliFHGrossmanE.Drug induced hypertension—An unappreciated cause of secondary hypertension. Eur J Pharmacol2015; 763: 15–22.
117.
de BonoJSLogothetisCJMolinaA, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med2011; 364: 1995–2005.
